News

BLOG UPDATES

Over recent weeks, Phil Thorne, our blogger reporting on all things medicinal chemistry has posted on a wide range of topics, from the prevalence of drug fraud through to the zika virus.

To read “Views from the Bench – a Chemist’s Blog” click the image below:

views from the bench masthead

Charnwood Molecular are seeking new recruits to join our growing team.

We are currently recruiting at various levels and invite applications from suitable candidates with backgrounds in the following areas:

• Synthetic Chemistry
• Medicinal Chemistry
• Process Research and Development

More details and information on applying are available here:

www.charwnood-molecular.com/careers/

Charnwood Molecular - Conferences Q1 2016

We have now finalised the conferences that we are attending early 2016.

If you would like further information on our participation in any of the following events, or would like to arrange to meet one of our representatives at any of the venues, please contact us via email at:

info@charnwood-molecular.com

Event: Mastering MedChem: 2nd RSC-BMCS Symposium
Date: 9 March 2016
Venue: University of Huddersfield

Event: Frontiers in Medicinal Chemistry
Date: 13-16 March 2016
Venue: Bonn, Germany

Event: 5th RSC/SCI Symposium on Ion channels as Therapeutic Targets
Date: 14-15 March 2016
Venue: Wellcome Genome Campus Conference Centre, Cambridge, UK

Event: Research & Innovation 2016
Date: 23 March 2016
Venue: Trent Vineyard, Nottingham

Paul @ Biocity

We were recently visited at our BioCity lab by Gemma Toulson, the Business Editor of the Nottingham Post.

Gemma put together a piece on Charnwood Molecular/the BioCity lab which featured in the newspaper a little while ago, but it is now available to view online here:

http://www.nottinghampost.com/Firm-s-formula-success/story-27573860-detail/story.html

Conferences 2015

Charnwood Molecular are involved in the following upcoming conferences, exhibitions and events over the next few months.
If you would like further information on our participation in any of these, or would like to arrange to meet one of our representatives at any of the venues, please contact us via email at:

info@charnwood-molecular.com

Event: The Expanding Toolbox of Medicinal Chemistry: From Chemical Biology to Clinical Applications
Date: 16 October 2015
Venue: Dijon, France

Event: 1st RSC/SCI Symposium on Fibrosis Disease: Medicinal Chemistry Progress from Biological Target to the Clinic
Date: 10 November 2015
Venue: UCB, Slough, UK

Event: United Kingdom Automated Synthesis Forum
Date: 11-12 November 2015
Venue: Nottingham, UK

Event: SCI Academic Drug Discovery III
Date: 24 November 2015 SCI, London, UK
Venue: SCI, London, UK

Event: Society for Medicines Research: Trends in Medicinal Chemistry
Date: 3 December 2015
Venue: NHLI, London, UK

conferences  2015

We are in the process of arranging our forthcoming events and conference schedule for the rest of 2015.

Our scientists will be present at the following events and we’d be happy to meet to discuss our outsourcing offering:

Event: ELRIG Drug Discovery 2015
Date: 2-3 September 2015
Venue: Telford, UK

Event: 18th SCI/RSC Medicinal Chemistry Symposium: Drugging the Undruggable
Date: 13-16 September 2015
Venue: Churchill College, Cambridge, UK

Event: FMC 2015 Frontiers in Medicinal Chemistry
Date: 14-16 September 2015
Venue: Antwerp, Belgium

Event: The Expanding Toolbox of Medicinal Chemistry: From Chemical Biology to Clinical Applications
Date: 16 October 2015
Venue: Dijon, France

Should you wish to arrange a meeting in advance at any of these events, please contact:

Robin Wilkes
email: r.wilkes@charnwood-molecular.com

Charnwood Molecular Joint Venture

Charnwood Molecular’s recent partnership to launch a new service identifying interactions between small molecules and protein targets has received recognition within the European Eurostars programme that part funded its development.

Working with French company, Hybrigenics, Charnwood used its expertise to link molecules for further analysis by the Paris-based company, using their yeast molecular biology machinery.

The venture is the result of a two year long commercial trialling phase, which was supported by European funding under the Eurostars programme.

ULTImate YChemH is a chemical biology tool for direct targets identification. This method is based on the well-established yeast two-hybrid (Y2H) technology.

More details are available on the Eurostars website here:

https://www.eurostars-eureka.eu/content/eurostars-project-hybry3chem?_ga=1.265490383.1183287846.1415797399

Conferences 2015

We have now finalised our forthcoming events and conference schedule for the next part of 2015. This list may be added to, but so far we have confirmed attendance at the following International events.

Our representatives will be in attendance and we’d be happy to meet there to discuss any aspect of your business that you feel Charnwood Molecular can assist with:

Event: World Preclinical Congress: Mastering Med Chem & Property-Based Drug Design
Date: 10-12 June 2015
Venue: Boston, MA, USA

Event: RICT 2015 Drug Discovery and Selection: Understanding Targets and Mechanisms
Date: 1-3 July 2015
Venue: Avignon, France

Event: Spanish-Italian Med Chem Congress (SIMCC-2015)
Date: 12-15 July 2015
Venue: Barcelona, Spain

Event: 18th SCI/RSC Medicinal Chemistry Symposium: Drugging the undruggable
Date: 13-16 September 2015
Venue: Churchill College, Cambridge, UK

Should you wish to arrange a meeting in advance at any of these events, please contact:

Robin Wilkes
email: r.wilkes@charnwood-molecular.com

KONICA MINOLTA DIGITAL CAMERA

As part of the ongoing growth and development of its business, Charnwood Molecular has secured the services of Dr. David Lathbury.

Dr Lathbury has over 25 years of industrial experience in the fine chemical, agrochemical, and pharmaceutical fields. Over the last 20 years he has worked in the pharmaceutical arena at SmithKline Beecham, and at AstraZeneca, where he was Head of Process Chemistry. Most recently he was Vice President of Chemical Development at Albany Molecular Research in Syracuse, New York.

During his extensive career, David has worked on four marketed drugs, including process re-development activities on “Seroquel” and “Paxil”. During his time at AstraZeneca, his team was responsible for the chemical development of “Iressa” and “Crestor”. He is author or co-author on 30 publications and patents.

David is a Fellow of the Royal Society of Chemistry and is a visiting Professor at Bristol University. He is also a member of the EPSRC strategic advisory team and was Chair of the 2012 Gordon Research Conference on Heterocyclic Compounds.

David will now work with a team of experienced scientists at Charnwood Molecular to build a unique and sector-leading Chemical and Process Development service to add to Charnwood’s existing Contract Research activities in Medicinal Chemistry, Custom Synthesis and Contract Research.

For more information, please contact Dr. Robin Wilkes, Director of Business Development (Medicinal Chemistry) at r.wilkes@charnwood-molecular.com

Proteinase 2015

Charnwood Molecular is exhibiting at the forthcoming Proteinaise 2015 – 9th RSC / SCI symposium on Proteinase Inhibitor Design.

The event takes place from the 13th to 14th April, at Novartis, Basel, Switzerland.

This symposium will cover progress in the design and synthesis of protease inhibitors for a diverse range of disease indications, while also covering a range of novel drug discovery activities: from ‘Molecules to Medicines’. The event is aimed at medicinal chemists and other scientists interested in furthering their knowledge of proteases in the context of drug discovery.

Charnwood will be exhibiting at the event and explaining its expertise in drug discovery activities and process development.

If you are in attendance at the event and would like to meet, please email: r.wilkes@charnwood-molecular.com